FDA proposes Rx label revisions for moms

Share this article:

The FDA on Wednesday announced it is proposing revisions to physician labeling for Rx drugs to include more info about their use by pregnant and/or breast-feeding mothers.

The proposed changes would give physicians more comprehensive information for making prescribing decisions and for counseling mothers and moms-to-be about medications, the agency said in a posting on its Web site.

“With this proposal, FDA's goal is to help women, their physicians and their pharmacists have better information about the effects of prescription medicines so that pregnant women, nursing mothers, and breast-feeding infants will benefit,” said Sandra Kweder of the FDA's Center for Drug Evaluation and Research.

The agency is soliciting electronic comments regarding the proposal over the next 90 days via the Federal Documents Management System/eRulemaking portal a www.regulations.govThe FDA said it will carefully consider the comments in preparing a final rule.

More information on the FDA proposal is available at: http://www.fda.gov/cder/regulatory/pregnancy_labeling/default.htm.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.